Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17505
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParrott, Andrew C-
dc.contributor.authorDowney, Luke A-
dc.contributor.authorRoberts, Carl A-
dc.contributor.authorMontgomery, Cathy-
dc.contributor.authorBruno, Raimondo-
dc.contributor.authorFox, Helen C-
dc.date2017-06-29-
dc.date.accessioned2018-04-24T05:33:15Z-
dc.date.available2018-04-24T05:33:15Z-
dc.date.issued2017-08-
dc.identifier.citationJournal of psychopharmacology (Oxford, England) 2017; 31(8): 959-966-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17505-
dc.description.abstractThe purpose of this article is to debate current understandings about the psychobiological effects of recreational 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'), and recommend theoretically-driven topics for future research. Recent empirical findings, especially those from novel topic areas were reviewed. Potential causes for the high variance often found in group findings were also examined. The first empirical reports into psychobiological and psychiatric aspects from the early 1990s concluded that regular users demonstrated some selective psychobiological deficits, for instance worse declarative memory, or heightened depression. More recent research has covered a far wider range of psychobiological functions, and deficits have emerged in aspects of vision, higher cognitive skill, neurohormonal functioning, and foetal developmental outcomes. However, variance levels are often high, indicating that while some recreational users develop problems, others are less affected. Potential reasons for this high variance are debated. An explanatory model based on multi-factorial causation is then proposed. A number of theoretically driven research topics are suggested, in order to empirically investigate the potential causes for these diverse psychobiological deficits. Future neuroimaging studies should study the practical implications of any serotonergic and/or neurohormonal changes, using a wide range of functional measures.-
dc.language.isoeng-
dc.subject3,4-methylenedioxymethamphetamine-
dc.subjectEcstasy-
dc.subjectcentral nervous system-
dc.subjectcognition-
dc.subjectmemory-
dc.subjectpsychobiology-
dc.subjectstimulant-
dc.titleRecreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of psychopharmacology (Oxford, England)-
dc.identifier.affiliationDepartment of Psychology, Swansea University, Swansea, UK-
dc.identifier.affiliationCentre for Human Psychopharmacology, Swinburne University, Melbourne, Australia-
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationInstitute of Psychology, Health and Society, University of Liverpool, Liverpool, UK-
dc.identifier.affiliationSchool of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK-
dc.identifier.affiliationSchool of Medicine, University of Tasmania, Hobart, Australia-
dc.identifier.affiliationDepartment of Psychiatry, Stony Brook University, New York, USA-
dc.identifier.doi10.1177/0269881117711922-
dc.identifier.pubmedid28661257-
dc.type.austinJournal Article-
dc.type.austinReview-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.